Novartis AG ADR

Novartis AG ADR

Yahoo Finance • 16 hours ago

Atrial Fibrillation Market Trends and Forecast 2026-2035 Featuring Profiles of Abbott, Boston Scientific, Medtronic, Johnson & Johnson, Novartis, and Sanofi

Company Logo Antiarrhythmic agents account for around 55% of the therapy landscape, while monoclonal antibodies are emerging as an investigational approach Atrial Fibrillation MarketAtrial Fibrillation Market Dublin, Aug. 26, 2026 (GLOB... Full story

Yahoo Finance • 16 hours ago

Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus

The Fidelity MSCI Health Care Index ETF (NYSEMKT:FHLC) provides broad, low-cost exposure to the entire healthcare sector, whereas the VanEck Pharmaceutical ETF (NASDAQ:PPH) offers a concentrated, higher-yielding focus on global pharmaceuti... Full story

Yahoo Finance • 3 days ago

Melexis: update on the share buy-back program

Melexis N.V. Press release - Regulated Information Melexis: update on the share buy-back program Ieper, Belgium – 24 August 2026, 17.45 hrs CET Melexis reports the purchase of 3,919 Melexis shares on Euronext Brussels in the period fro... Full story

Yahoo Finance • 3 days ago

NKT qualifies 525 kV HVDC subsea power cable system for operation at 90 °C

COPENHAGEN, Denmark, Aug. 24, 2026 /PRNewswire/ -- NKT launches a fully qualified 525 kV HVDC power cable system for operation with a 90 °C conductor temperature. This enables increased transmission capability, strengthening the performanc... Full story

Yahoo Finance • 6 days ago

SBO AG (SBOEY) (Q2 2026) Earnings Call Highlights: Trend Reversal as Sales Grow for First Time ...

This article first appeared on GuruFocus. Group Sales (H1 2026): Decreased by 19.3% year-over-year to $2.05 billion from $2.54 billion, impacted by a weaker US dollar (approximately $12 million FX impact). Group Sales (Q2 2026): Increased... Full story

Yahoo Finance • 6 days ago

RaySearch Laboratories AB (RSLBF) (Q2 2026) Earnings Call Highlights: Order Intake Surges 23% ...

This article first appeared on GuruFocus. Net Sales (Q2 2026): SEK272 million, a decrease of 11% year-over-year, with organic growth of negative 8%. Net Sales (Last 12 Months): SEK1.27 billion, with organic growth of 9%. Operating Profit... Full story

Yahoo Finance • 7 days ago

Novartis (SWX:NOVN) Lines Up Pivotal Cardiovascular Data For ESC 2026

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Novartis (SWX:NOVN) plans to present late breaking data from multiple pivotal cardiovascular stu... Full story

Yahoo Finance • 7 days ago

Palantir Stock Climbs as Enterprise AI Demand Keeps Growing

This article first appeared on GuruFocus. Palantir Technologies (NASDAQ:PLTR) stock gained 1% on Wednesday morning. The tech company is using a second AI Sovereignty Bootcamp to broaden engagement with organizations evaluating its artific... Full story

Yahoo Finance • 8 days ago

Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play

Quick Read AKTS retains full worldwide rights to its alpha-emitting cancer platform, with $517M cash and binary Q1 2027 trial data looming. NVS, whose Pluvicto grew 43% in Q2 2026, and LLY, already a $60M upfront partner, rank as the top... Full story

Yahoo Finance • 8 days ago

Palantir's Sovereignty Bootcamps Draw Nearly 200 Organizations in <30 Days

MIAMI, August 19, 2026--(BUSINESS WIRE)--Palantir Technologies Inc. (NASDAQ: PLTR) today announced its second Sovereignty Bootcamp in <30 days. On the back of unprecedented demand for its Inaugural Sovereignty Bootcamp, held on July 27, Pa... Full story

Yahoo Finance • 8 days ago

Trump expected to nominate White House aide Heidi Overton as FDA commissioner

[FDA Headquarters] President Donald Trump is expected to tap Heidi Overton, a top aide at the White House’s Domestic Policy Council, to serve as the next commissioner of the Food and Drug Administration, according to multiple media report... Full story

Yahoo Finance • 8 days ago

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

Novartis Pharma AG Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goals New AZALEA-TIMI 71 analyses will further characterize the bleeding profile of abelacimab i... Full story

Yahoo Finance • 9 days ago

PPH vs. IYH: Which Healthcare Fund Is the Better Buy?

Investors looking at the VanEck Pharmaceutical ETF (NASDAQ:PPH) and the iShares U.S. Healthcare ETF (NYSEMKT:IYH) are really deciding between a concentrated bet on drugmakers and broad exposure to the entire domestic medical ecosystem. Bo... Full story

Yahoo Finance • 9 days ago

Ondas to Acquire Aran Defense, Strengthening Israel's Sovereign Defense-Industrial Base

Aran Defense is a defense-focused division of Aran Ltd. (TASE:ARAN), an established Israeli engineering and manufacturing company serving governmental customers in Israel, as well as leading international defense companies Acquisition wil... Full story

Yahoo Finance • 13 days ago

NKT AS (NRKBY) (Q2 2026) Earnings Call Highlights: Margin Expansion and Raised EBITDA Guidance ...

This article first appeared on GuruFocus. Revenue: EUR657 million in Q2 2026, down from EUR723 million in Q2 2025, reflecting an organic growth decline of 9%. Operational EBITDA: Stable at EUR104 million, compared to EUR105 million in Q2... Full story

Yahoo Finance • 14 days ago

Update: Market Chatter: Novartis Wins UK Court Challenge to Entresto Patent

(Updates with response from a Novartis spokesperson in the fourth and fifth paragraphs.)Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection c... Full story

Yahoo Finance • 15 days ago

SBO Strengthens Position in 3D Metal Printing: Expanded Capacity in the US and the UK, Award for 3T

TERNITZ, AUSTRIA - August 11, 2026 (NEWMEDIAWIRE) - SBO AG, listed on the leading index ATX of the Vienna Stock Exchange, is expanding its 3D metal printing capacity in the US and the UK and strengthening its market position in Europe thro... Full story

Yahoo Finance • 16 days ago

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

Quick Read LEGN surged 6% as Q2 revenue of $388M beat estimates and adjusted EPS of $0.16 doubled consensus, marking the company's first-ever profitable quarter. CARVYKTI net sales hit $657M, up 50%, with JNJ co-developer Janssen supporti... Full story

Yahoo Finance • 16 days ago

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchi... Full story

Yahoo Finance • 16 days ago

The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"

A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life science... Full story